Generate QR code
Open Access
Subscription Access
Immune status of liver transplant patients receiving combined local and systemic mesenchymal stem cell therapy
https://doi.org/10.29235/1818-9857-2025-11-78-83
Abstract
Evaluate the effect of combined local and systemic therapy with mesenchymal stem cells (MSCs) on the immunophenotypic profile (IPT) of peripheral blood mononuclear cells (PBMCs) in patients after liver transplantation. Materials and methods: In a randomized prospective study, 30 patients received MSC therapy, while 30 patients were on standard immunosuppressive therapy. IPT of PBMCs was performed using multicolor flow cytometry. Functional parameters of the graft, tacrolimus concentration, morphological signs of rejection, and clinical outcomes were evaluated.
The MSC group showed faster functional recovery of the graft with accelerated decrease in ALT levels on days 7 and 10 (p< 0.05) with significantly lower tacrolimus concentration throughout the observation period. The frequency of immune-mediated graft dysfunction in both groups was 20%; however, the MSC group showed a lower rejection activity index (RAI 6 (4; 7) versus 7 (4; 8) points) and no cases of humoral rejection. IPT revealed a decrease in the absolute number of CD16+56+ natural killer cells, CD3+CD4+ and CD3+CD8+ effector memory T cells, naive mature B lymphocytes, and marginal zone B cells, with increased levels of myeloid and plasmacytoid dendritic cells and immunosuppressive B1a lymphocytes in the MSC group.
About the Authors
S. Korotkov
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Sergey Korotkov
V. Smolnikova
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Victoria Smolnikova
V. Grinevich
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Victoria Grinevich
O. Korotkov
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Oleg Korotkov
D. Efimov
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Denis Efimov
S. Krivenko
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Svetlana Krivenko
O. Rummo
МНПЦ хирургии, трансплантологии и гематологии
Belarus
Belarus
Oleg Rummo
References
1. EASL Clinical Practice Guidelines on liver transplantation / D. Samuel [et al.] // Journal of Hepatology. 2024. Vol. 81, №6. P. 1040–1086. Https://doi.org/10.1016/j.jhep.2024.07.032.
2. Antibody mediated rejection in liver transplantation: immunopathological characteristics and longterm follow-up / L. Cicalese [et al.] // Transplant International. 2024. Vol. 37. P. 132–132. Https://doi.org/10.3389/ti.2024.13232.
3. Sensing acute cellular rejection in liver transplant patients using liver derived extracellular particles: a prospective, observational study / K. Kamali [et al.] // Frontiers in Immunology. 2021. Vol. 12. P. 6479–6500. Https://doi.org/fimmu.2021.647900.
4. Longterm outcomes of patients undergoing liver transplantation for acute on chronic liver failure / V. Sundaram [et al.] // Liver Transplantation. 2020. Vol. 26, N12. P. 1594–1602. Https://doi.org/10.1002/lt.25831.
5. Immunosuppressive drugs in liver transplant: an insight / C. Panackel, J. F. Mathew, M. Fawas, M. Jacob // Journal of Clinical and Experimental Hepatology. 2022. Vol. 12, №6. P. 1557–1571. Https://doi.org/10.1016/j.jceh.2022.06.007.
6. Rationale for the potential use of mesenchymal stromal cells in liver transplantation / M. Vandermeulen [et al.] // World Journal of Gastroenterology. 2014.Vol. 20, №44. P. 16418–16432. Https://doi.org/10.3748/wjg.v20.i44.16418.
7. Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties / F. Wen [et al.] // Stem Cell Research and Therapy. 2024. Vol. 15, №320. P. 1–12. Https://doi.org/10.1186/s13287-024-03943-6.
8. Применение мезенхимальных стромальных клеток при трансплантации солидных органов: вызовы и перспективы / Ю.Б. Басок [и др.] // Вестник трансплантологии и искусственных органов. 2025. Т. XXVII, №1. С. 114–134. Https://doi.org/10.15825/1995-1191-2025-1-114-134.
9. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial / Q. Sun [et al.] // Journal of Translational Medicine. 2018. Vol. 16, №.52. P. 1–10. Https://doi.org/10.1186/s12967-018-1422-x.
10. Клинический протокол «Трансплантация печени (взрослое и детское население)» (утвержден МЗ РБ 13.02.2023 №31) // http://minzdrav.gov.by.
11. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement / M. Dominici [et al.] // Cytotherapy. 2006. Vol. 8, №4. P. 315–317. Https://doi.org/10.1080/14653240600855905.
12. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study / Peng Y. [et al.] // Transplantation. 2013. Vol. 95, №1. P. 161–168. Https://doi.org/10.1097/TP.0b013e3182754c53.
13. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction / A. Morelli, A. Thomson // Immunol. Rev. 2004. Vol. 196, №11. P. 125–46. Https://doi.org/10.1046/j.1600-065X.2003.00079.x.
14. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity / Y. Liu // Cell. 2001. Vol. 106, №3. P. 259–262. Https://doi.org/10.1016/s0092-8674(01)00456-1.
15. СD4+ Т-клетки и их субпопуляции как прогностический маркер острого отторжения при трансплантации почки / С. Коротков [и др.] // Наука и инновация. 2016. №8. С. 33–36.
16. Эффекторные CD4+ Т-лимфоциты и дендритные клетки – неинвазивные биомаркеры позднего клеточного отторжения при трансплантации почки / А. Носик [и др.] // Трансплантология. 2018. Т. 10, №3. С. 207–216.
Review
For citations:
Korotkov S., Smolnikova V., Grinevich V., Korotkov O., Efimov D., Krivenko S., Rummo O. Immune status of liver transplant patients receiving combined local and systemic mesenchymal stem cell therapy. Science and Innovations. 2025;(11):78-83. (In Russ.) https://doi.org/10.29235/1818-9857-2025-11-78-83
Views:
22
Email this article 